CSF VEGF Was Positively Associated with Neurogranin Independent of β-Amyloid Pathology
Authors Huang Y, Wang J, Zhu B, Fu P
Received 1 March 2020
Accepted for publication 21 April 2020
Published 22 July 2020 Volume 2020:16 Pages 1737—1744
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yuping Ning
Yangping Huang, Jun Wang, Bihong Zhu, Pan Fu
Department of Neurology, Taizhou First People’s Hospital, Taizhou, Zhejiang, People’s Republic of China
Correspondence: Pan Fu Email [email protected]
Purpose: Increasing evidence suggests that both vascular endothelial growth factor (VEGF) and synaptic failure have been involved in the pathogenesis of Alzheimer’s disease (AD). However, it is not clear whether CSF VEGF levels are associated with synaptic function in living human.
Patients and Methods: In the present study, we included a total of 291 older individuals, including 83 individuals with normal cognition (NC), 143 individuals with mild cognitive impairment (MCI) and 65 patients with AD. Several linear regression models were conducted to examine the associations of CSF VEGF with CSF neurogranin levels (NG, reflecting synaptic degeneration) when controlling for other potential confounding factors, including age, gender, years of education, clinical diagnosis, APOE4 genotype and CSF β-amyloid 42 (Aβ 42) levels.
Results: There was no significant difference in VEGF levels between the three diagnostic groups. In the pooled sample, females had significantly lower levels of VEGF than males. Aβ-positive (CSF Aβ 42 < 192 pg/mL) individuals had lower levels of VEGF than Aβ-negative individuals. However, the relationships between VEGF and NG levels were not modified by disease stage. Finally, we found that CSF VEGF levels were associated with NG levels with adjustment of age, gender, years of education, clinical diagnosis, APOE4 genotype and CSF Aβ 42 levels.
Conclusion: CSF VEGF levels were associated with NG independent of AD pathology and disease stage.
Keywords: vascular endothelial growth factor, neurogranin, synaptic dysfunction, Alzheimer’s disease
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]